Search results
Results From The WOW.Com Content Network
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
A 2014 Cochrane Systematic Review studied the effectiveness of ranibizumab and pegaptanib, on patients who have macular edema caused by central retinal vein occlusion. [5] Participants in both treatment groups showed improvement in visual acuity measures and a reduction in macular edema symptoms over six months.
The diagnosis of branch retinal vein occlusion is made clinically by finding retinal hemorrhages in the distribution of an obstructed retinal vein. Fluorescein angiography is a helpful adjunct. Findings include delayed venous filling, hypofluorescence caused by hemorrhage and capillary nonperfusion, dilation and tortuosity of veins, leakage due ...
Retinal hemorrhage (UK English: retinal haemorrhage) is a disorder of the eye in which bleeding occurs in the retina, the light sensitive tissue, located on the back wall of the eye. [1] There are photoreceptor cells in the retina called rods and cones , which transduce light energy into nerve signals that can be processed by the brain to form ...
The central retinal vein is the venous equivalent of the central retinal artery and both may become occluded. [1] Since the central retinal artery and vein are the sole source of blood supply and drainage for the retina , such occlusion can lead to severe damage to the retina and blindness, due to ischemia (restriction in blood supply) and ...
Central retinal artery occlusion: CRAO is characterized by painless, acute vision loss in one eye. [11] Central retinal vein occlusion: CRVO causes sudden, painless vision loss that can be mild to severe. [12] Branch retinal vein occlusion: sudden painless vision loss or visual field defect are the main symptom of BRVO. [13]
Central retinal artery occlusion is a known feature of non-proliferative sickle cell retinopathy that has a low incidence in patients with non proliferative sickle cell retinopathy. [ 5 ] Optic nerve sign is represented by dilated capillaries that can be visualized in the nerve using fluorescein angiography.
Currently there is no treatment for this condition, but, it is usually self limiting. [1] Systemic administration of corticosteroids may be advised. [2] Even if the disease is resolved, the enlarged blind spot usually does not return to normal. [5]